Susquehanna International Group, LLP Bei Gene, Ltd. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $4 Million - $6.24 Million	-27,800 Reduced 37.47%	46,400 $10.4 Million
Q2 2024 Aug 15, 2024	BUY	$129.52 - $174.32 $582,840 - $784,440	4,500 Added 6.46%	74,200 $10.6 Million
Q1 2024 May 07, 2024	BUY	$141.8 - $181.47 $4.64 Million - $5.93 Million	32,700 Added 88.38%	69,700 $10.9 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $2.81 Million - $3.57 Million	17,700 Added 91.71%	37,000 $6.67 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $4.51 Million - $5.65 Million	-25,100 Reduced 56.53%	19,300 $3.47 Million
Q2 2023 Aug 11, 2023	BUY	$178.3 - $266.78 $142,640 - $213,423	800 Added 1.83%	44,400 $7.92 Million
Q1 2023 May 16, 2023	BUY	$215.53 - $274.5 $991,438 - $1.26 Million	4,600 Added 11.79%	43,600 $9.4 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $3.51 Million - $6.42 Million	28,000 Added 254.55%	39,000 $8.58 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $250,420 - $384,256	1,900 Added 20.88%	11,000 $1.48 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.